Growth Metrics

Cme (CME) EBIT Margin (2016 - 2025)

Cme (CME) has disclosed EBIT Margin for 17 consecutive years, with 61.84% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 25.0% to 61.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 64.86%, a 73.0% increase, with the full-year FY2025 number at 64.86%, up 73.0% from a year prior.
  • EBIT Margin was 61.84% for Q4 2025 at Cme, down from 63.25% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 67.47% in Q1 2025 to a low of 55.06% in Q4 2021.
  • A 5-year average of 61.37% and a median of 61.75% in 2025 define the central range for EBIT Margin.
  • Biggest YoY gain for EBIT Margin was 818bps in 2021; the steepest drop was -521bps in 2021.
  • Cme's EBIT Margin stood at 55.06% in 2021, then grew by 0bps to 55.33% in 2022, then increased by 8bps to 59.97% in 2023, then rose by 4bps to 62.09% in 2024, then decreased by 0bps to 61.84% in 2025.
  • Per Business Quant, the three most recent readings for CME's EBIT Margin are 61.84% (Q4 2025), 63.25% (Q3 2025), and 66.74% (Q2 2025).